{"id":53405,"date":"2023-01-30T13:02:35","date_gmt":"2023-01-30T12:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/"},"modified":"2023-01-30T13:02:35","modified_gmt":"2023-01-30T12:02:35","slug":"charles-river-laboratories-acquires-samdi-tech","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/","title":{"rendered":"Charles River Laboratories Acquires SAMDI Tech"},"content":{"rendered":"
\n

\n\u2013 Proprietary Mass Spectrometry Technology Delivering Innovative High-Throughput Screening Capabilities to Accelerate Drug Discovery Timelines \u2013<\/b>\n<\/p>\n

\n\u2013 Advances Partnership Initiated in 2018 \u2013<\/b>\n<\/p>\n

WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL<\/a> #CRL<\/a>–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc<\/a>, a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition marks the culmination of a partnership between the companies that began in 2018.\n<\/p>\n

<\/a><\/p>\n

\nBased in Chicago, Illinois, SAMDI Tech offers a proprietary mass spectrometry (MS) technology for high-throughput analysis of biochemical activities and affinity selection MS (SAMDI ASMS) for identifying binding interactions. The technology minimizes false positive results, reduces reagent requirements, and offers multiplexing capabilities without restricting assay conditions. These solutions are increasingly favored by clients to accelerate the timeline and reduce costs to identify a lead drug candidate, drive more effective research and high-quality scientific data, and enable clients to make critical go-no-go decisions earlier and advance their projects more efficiently. SAMDI Tech\u2019s comprehensive drug discovery solutions also include optical and radioactivity capabilities, cell-based assays, and an in-house collection of over a half million drug-like small molecules.\n<\/p>\n

\nThe combination of Charles River\u2019s end-to-end portfolio and industry-leading scientific expertise with SAMDI Tech\u2019s innovative MS technology and expertise in assay solutions has the potential to significantly accelerate and augment clients\u2019 discovery efforts by measuring biochemical activities and identifying binding interactions for virtually any small molecule drug target. The acquisition will provide Charles River\u2019s clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, industry-leading library of drug discovery solutions.\n<\/p>\n

\nJames C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, \u201cThe acquisition of SAMDI Tech\u2019s cutting-edge, high-throughput screening technology further strengthens Charles River\u2019s drug discovery capabilities and enhances our unique ability to serve as an integrated partner to support our clients\u2019 early-stage research. SAMDI Tech\u2019s platform combined with our premier, end-to-end drug discovery portfolio will generate better data and faster hit identification and is another step to accelerate our clients\u2019 drug discovery efforts. With over a decade of industry experience and the successful, existing partnership, we believe the addition of SAMDI Tech will continue to generate new business opportunities and we are pleased to welcome them to the Charles River family.\u201d\n<\/p>\n

\nFinancial and Transaction Details<\/span><\/b>\n<\/p>\n

\nThe purchase price was $50 million in cash for the remaining 80% ownership stake in SAMDI Tech that Charles River did not already own, subject to customary post-closing adjustments. Additional financial details were not disclosed as the transaction is not expected to have a material impact on Charles River\u2019s financial results in 2023. SAMDI Tech will become part of the Company\u2019s Discovery and Safety Assessment segment.\n<\/p>\n

\nCaution Concerning Forward-Looking Statements<\/span><\/b>\n<\/p>\n

\nThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201coutlook,\u201d and \u201cproject,\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements include statements in this press release regarding the impact of the acquisition on clients\u2019 businesses and on Charles River\u2019s financial results. Forward-looking statements are based on Charles River\u2019s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River’s Annual Report on Form 10-K as filed on February 16, 2022, and the Quarterly Report on Form 10-Q as filed on November 2, 2022, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.\n<\/p>\n

\nAbout Charles River<\/b>\n<\/p>\n

\nCharles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
Todd Spencer
\n
Corporate Vice President,
\n
Investor Relations
\n
781.222.6455
\n
todd.spencer@crl.com<\/a>\n<\/p>\n

\nMedia Contact:
\n
Amy Cianciaruso
\n
Corporate Vice President,
\n
Chief Communications Officer
\n
781.222.6168
\n
amy.cianciaruso@crl.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Proprietary Mass Spectrometry Technology Delivering Innovative High-Throughput Screening Capabilities to Accelerate Drug Discovery Timelines \u2013 \u2013 Advances Partnership Initiated in 2018 \u2013 WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-53405","format-standard","category-industry"],"yoast_head":"\nCharles River Laboratories Acquires SAMDI Tech - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles River Laboratories Acquires SAMDI Tech - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Proprietary Mass Spectrometry Technology Delivering Innovative High-Throughput Screening Capabilities to Accelerate Drug Discovery Timelines \u2013 \u2013 Advances Partnership Initiated in 2018 \u2013 WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T12:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230130005075\/en\/836653\/21\/charles_river_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Charles River Laboratories Acquires SAMDI Tech\",\"datePublished\":\"2023-01-30T12:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/\"},\"wordCount\":798,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005075\\\/en\\\/836653\\\/21\\\/charles_river_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/\",\"name\":\"Charles River Laboratories Acquires SAMDI Tech - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005075\\\/en\\\/836653\\\/21\\\/charles_river_logo.jpg\",\"datePublished\":\"2023-01-30T12:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005075\\\/en\\\/836653\\\/21\\\/charles_river_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230130005075\\\/en\\\/836653\\\/21\\\/charles_river_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/charles-river-laboratories-acquires-samdi-tech\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Charles River Laboratories Acquires SAMDI Tech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles River Laboratories Acquires SAMDI Tech - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/","og_locale":"en_US","og_type":"article","og_title":"Charles River Laboratories Acquires SAMDI Tech - Pharma Trend","og_description":"\u2013 Proprietary Mass Spectrometry Technology Delivering Innovative High-Throughput Screening Capabilities to Accelerate Drug Discovery Timelines \u2013 \u2013 Advances Partnership Initiated in 2018 \u2013 WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-30T12:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230130005075\/en\/836653\/21\/charles_river_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Charles River Laboratories Acquires SAMDI Tech","datePublished":"2023-01-30T12:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/"},"wordCount":798,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005075\/en\/836653\/21\/charles_river_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/","url":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/","name":"Charles River Laboratories Acquires SAMDI Tech - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230130005075\/en\/836653\/21\/charles_river_logo.jpg","datePublished":"2023-01-30T12:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230130005075\/en\/836653\/21\/charles_river_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230130005075\/en\/836653\/21\/charles_river_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/charles-river-laboratories-acquires-samdi-tech\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Charles River Laboratories Acquires SAMDI Tech"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53405"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53405\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}